SynapCell is a French simplified joint-stock company founded in 2005 and located at Grenoble, France.
To our mind, it is essential to identify the best drug candidates as early as the preclinical step in order to improve clinical development efficiency.
We are deeply convinced that this improvement relies on the development of both translational models and cutting-edge processes.
QUALIFY the therapeutic potential of your lead compounds through our highly predictive solutions.
PROVIDE a great added value to your drug candidates with a precise targeting of their future indication.
OPTIMIZE your CNS drug development by increasing the probability of clinical success whilst saving valuable time and money.